ERBB2 and breast carcinoma: While pCR rates are generally higher in recent, international trials with combination chemotherapy regimens for TNBC and HER2+ breast cancers, these trials have a large percentage of T1-2 tumors [64, 66] where pCR rates are expectedly higher.